Tolerability of Diquas LX on tear film and meibomian glands findings

Tolerability of Diquas LX on tear film and meibomian glands findings - Tolerability of Diquas LX on objective findings

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054378

Enrollment

Registered

2024-05-12

Start date

2023-07-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eye

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects were DE patients who had been on DQS eye drops at Itoh Clinic for more than 3 months and switched to DQS-LX, who requested to switch back to the original DQS within 1 month, and those who continued to use DQS as is.

Exclusion criteria

Exclusion criteria: Those that have not had DQS eye drops for more than 3 months

Design outcomes

Primary

Measure	Time frame
For patients who switched to DQS-LX after 3 or more months of continuous DQS eye drops and wished to return to DQS-LX within 1 month, the test items were measured in the meiboscore at the time of DQS-LX switch and compared to those who did not wish to do so.	—

Secondary

Measure	Time frame
For patients who switched to DQS-LX after more than 3 months of continuous DQS eye drops and wished to return to DQS-LX within 1 month, the following test items were measured at the time of DQS-LX switch: subjective symptoms (SPEED), tear film stability (BUT), tear film meniscus (TMH), corneal and conjunctival epithelial staining (CFS), conjunctival hyperemia/papule, Plugging, Vascularity, meibum grade, and Schirmer values were measured and compared to those not desired.	—

Measure

Time frame

For patients who switched to DQS-LX after more than 3 months of continuous DQS eye drops and wished to return to DQS-LX within 1 month, the following test items were measured at the time of DQS-LX switch: subjective symptoms (SPEED), tear film stability (BUT), tear film meniscus (TMH), corneal and conjunctival epithelial staining (CFS), conjunctival hyperemia/papule, Plugging, Vascularity, meibum grade, and Schirmer values were measured and compared to those not desired.

—

Countries

Japan

Contacts

Public ContactReiko Arita

Itoh Clinic Ophthalmology

ritoh@za2.so-net.ne.jp0486865588

Outcome results